Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing-based treatments for attenuating chronic disease
Company stage: Pre-clinical
Diseases (gene editing): Pulmonary Arterial Hypertension, PAH
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Binyamina, Israel
Lempo Therapeutics is an Israel-based, pre-clinical gene editing company, utilising CRISPR-Cas9 to edit stem-cells ex vivo, to inactivate disease causing myeloperoxidase (MPO) proteins in patients suffering from pulmonary arterial hypertension. Using CRISPR, Lempo edits CD34+ cells to knock out the MPO gene, after which the cells can be reinfused into patients.